AAAAAA

   
Results: 1-7 |
Results: 7
Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects
Authors: Degen, L Matzinger, D Merz, M Appel-Dingemanse, S Osborne, S Luchinger, S Bertold, R Maecke, H Beglinger, C
Citation: L. Degen et al., Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects, ALIM PHARM, 15(11), 2001, pp. 1745-1751
Tegaserod coadministration does not alter the pharmacokinetics of theophylline in healthy subjects
Authors: Zhou, H Khalilieh, S Svendsen, K Pommier, F Osborne, S Appel-Dingemanse, S Lasseter, K McLeod, JF
Citation: H. Zhou et al., Tegaserod coadministration does not alter the pharmacokinetics of theophylline in healthy subjects, J CLIN PHAR, 41(9), 2001, pp. 987-993
The effects of tegaserod (HTF 919) on the pharmacokinetics and pharmacodynamics of digoxin in healthy subjects
Authors: Zhou, HH Horowitz, A Ledford, PC Hubert, M Appel-Dingemanse, S Osborne, S McLeod, JF
Citation: Hh. Zhou et al., The effects of tegaserod (HTF 919) on the pharmacokinetics and pharmacodynamics of digoxin in healthy subjects, J CLIN PHAR, 41(10), 2001, pp. 1131-1139
Multiple-dose pharmacokinetics confirm no accumulation and dose proportionality of the novel promotile drug tegaserod (HTF 919)
Authors: Appel-Dingemanse, S Hirschberg, Y Osborne, S Pommier, F McLeod, J
Citation: S. Appel-dingemanse et al., Multiple-dose pharmacokinetics confirm no accumulation and dose proportionality of the novel promotile drug tegaserod (HTF 919), EUR J CL PH, 56(12), 2001, pp. 889-891
Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients
Authors: Neumayer, HH Paradis, K Korn, A Jean, C Fritsche, L Budde, K Winkler, M Kliem, V Pichlmayr, R Hauser, IA Burkhardt, K Lison, AE Barndt, I Appel-Dingemanse, S
Citation: Hh. Neumayer et al., Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients, BR J CL PH, 48(5), 1999, pp. 694-703
Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration
Authors: Appel-Dingemanse, S Lemarechal, MO Kumle, A Hubert, M Legangneux, E
Citation: S. Appel-dingemanse et al., Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration, BR J CL PH, 47(5), 1999, pp. 483-491
A phase I study of a 4-week course of SDZ-RAD (RAD) in quiescent cyclosporine-prednisone-treated renal transplant recipients
Authors: Kahan, BD Wong, RL Carter, C Katz, SH Von Fellenberg, J Van Buren, CT Appel-Dingemanse, S
Citation: Bd. Kahan et al., A phase I study of a 4-week course of SDZ-RAD (RAD) in quiescent cyclosporine-prednisone-treated renal transplant recipients, TRANSPLANT, 68(8), 1999, pp. 1100-1106
Risultati: 1-7 |